glycobiology-Driven approaches against infectious diseases and antimicrobial resistance

Fighting infectious diseases differently

At AIS Biotech, we are developing a new generation of anti-infective biotherapies inspired by nature.
Our mission is to prevent and treat infection disease using glycomimetic biotherapeutics that mimic host-cell receptors to neutralize pathogens.

We believe the future of infectious disease management requires:

novel mechanisms of action
reduced risk of resistance
safer therapies

Our anti-infective biotherapies are designed to address:

viruses
antimicrobial resistance (AMR)
future emerging pathogens within a One Health approach

1 Billion

influenza infections yearly

10 Million

deaths/years by 2050 (AMR projection)

Increasing

pandemic preparedness needs

Sugar-based decoy receptors to trap pathogens

Many viruses and bacteria infect human cells by binding to specific sugars naturally present at the cell surface.
AIS Biotech develops innovative glycomimetics capable of neutralizing pathogens by mimicking their natural cellular receptors, preventing infection and limiting disease progression.

Many pathogens, including viruses and bacteria, bind to cell-surface sugars (oligosaccharides) as the first step of infection

AIS Biotech designs glycomimetic decoys that mimic natural receptors

Pathogens are trapped and neutralized. Attachment to host cells in blocked

A scalable glycobiotechnology platform

Using engineered bacterial strains, AIS Biotech produces complex custom oligosaccharides that mimic natural pathogen receptors.
These oligosaccharides are then assembled into multivalent biotherapeutics capable of neutralizing pathogens with high specificity.

bioengineered bacteria

metabolic engineering

high-cell density cultures

sustainable bioproduction

Key differenciators

First-in-class mechanism

Sustainable bioproduction

Low resistance risk

Broad pathogen applicability

Fast adaptability to emerging threats

A patient-driven vision.
We founded AIS Biotech to transform nature-inspired science into a new generation of therapies against infectious diseases.
By leveraging glycobiology and bioengineering, we aim to develop safer, smarter and more sustainable anti-infective therapies for patients worldwide
Aurélie Juhem, PhD
CEO & Co-founder,

Building a pipeline of next-generation anti-infectives

GLYCOFLU
TECHNOLOGY PLATFORM EXTENSION

Positioning

Prevention
Treatment
Pandemic preparedeness

Key benefits

Universal approach against Influenza A & B
No annual adaptation required
Nasal administration
Low resistance risk
Prophylactic & therapeutic use

Development status

Preclinical development
Clinical entry preparation

Beyond influenza…

AIS Biotech is leveraging its platform to develop additional anti-infective programs targeting pathogens that rely on sugar-mediated host attachment.
Our platform is already being applied to several high-value infectious disease targets beyond influenza, including viral and bacterial pathogens such as: